Chiome Bioscience Inc.'s share price showed a downward trend into early October, and on 6 October the company disclosed the publication of a paper and collaboration with Chiba University on an AMED project. In its financial results for the fiscal year ended August 2026, revenue was ¥274 million, up 8.7% year on year, while the operating loss narrowed to ¥480 million. The equity ratio improved to 81.9%.
Chiome Bioscience Inc.'s share price fell to ¥104 on 1 October and ¥96 on 8 October, and had still not fully recovered over the most recent 5 trading days.
On 6 October, the company disclosed the publication of a paper and collaboration with Chiba University on an AMED project, marking a period of intermittent communications concerning its drug discovery pipeline.
Financial results showed revenue of ¥274 million for the 2026 interim period, up 8.7% year on year, while the operating loss narrowed to ¥480 million. The equity ratio improved to 81.9%.
Performance over the past 12 quarters was viewed as likely to remain challenging, and attention was said to be warranted on trends in net profit margin and EPS.